Verapamil for Neuroprotection in Stroke

Part of paid clinical trials in Atlantic City, New Jersey.

Sponsor
Global Neurosciences Institute
Study ID
NCT03347786
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • 10 mg Intra-arterial Verapamil — DRUG
    Intra-arterial delivery of verapamil following mechanical thrombectomy procedure will be administered at a randomized dose of 10 mg or 20 mg to consenting patients.
  • 20 mg Intra-arterial Verapamil — DRUG
    Intra-arterial delivery of verapamil following mechanical thrombectomy procedure will be administered at a randomized dose of 10 mg or 20 mg to consenting patients.

Study Details

The purpose of this research study is to test an experimental procedure called intra-arterial delivery of verapamil in patients diagnosed with acute ischemic stroke. This study investigates the safety of intra-arterial delivery of verapamil, a drug used to treat vasospasm (spasm of a blood vessel), and how it affects recovery from stroke. Recruitment is limited to patients that have received mechanical thrombectomy as standard of care.

Key Dates

Start date
Apr 20, 2017
Status verified
Jan 2025
Primary completion
Aug 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Verapamil 10 mg Treatment Group
    Ischemic stroke patients with large penumbra are offered Verapamil treatment following mechanical thrombectomy. The patient will be randomly assigned an intervention group with the specified dose (10 mg) Verapamil.
  • Experimental: Verapamil 20 mg Treatment Group
    Ischemic stroke patients with large penumbra are offered Verapamil treatment following mechanical thrombectomy. The patient will be randomly assigned an intervention group with the specified dose (20 mg) Verapamil.

Primary Outcome Measure

Number of Participants with Bleeding Complications [ Time Frame: 3 months ]

Locations (3)

FacilityCityStateZIPSite coordinators
AtlantiCare Regional Medical CenterAtlantic CityNew Jersey08401
Rob Szapor, MBA, BSN, RN
[email protected]
609-345-4000
Mandy J Binning, MD (PRINCIPAL_INVESTIGATOR)
Erol Veznedaroglu, MD (PRINCIPAL_INVESTIGATOR)
Rudy Rahme, MD (SUB_INVESTIGATOR)
Kenneth Liebman, MD (SUB_INVESTIGATOR)
Zakaria Hakma, MD (SUB_INVESTIGATOR)
St Mary Medical CenterLanghornePennsylvania19047
Mary Dawson, Research Manager
[email protected]
215-710-2000
Mandy J Binning, MD (PRINCIPAL_INVESTIGATOR)
Erol Veznedaroglu, MD (PRINCIPAL_INVESTIGATOR)
Rudy Rahme, MD (SUB_INVESTIGATOR)
Kenneth Liebman, MD (SUB_INVESTIGATOR)
Zakaria Hakma, MD (SUB_INVESTIGATOR)
Crozer Chester Medical CenterUplandPennsylvania19013-

Find similar trials in Atlantic City, NJ

By condition
Stroke
By specialty
NeurologyBrain disorders
By research site
AtlantiCare Regional Medical Center· Atlantic City, NJSt Mary Medical Center· Langhorne, PACrozer Chester Medical Center· Upland, PA

Related Studies